Transcat is a defensive compliance compounder, using sticky regulated calibration services, high-margin rentals, and disciplined acquisitions to turn fragmented metrology markets into durable cash-flow growth.
Transcat Inc. (TRNS) is a highly specialized commercial metrology operator and value-added distributor of professional-grade test, measurement, and control instrumentation.[1, 2, 3] The company operates a dual-segment business model consisting of Services and Distribution, which function in a highly complementary manner.[1, 2] The Service segment represents approximately 65.5% of full-year consolidated revenue and focuses on the accredited calibration, repair, inspection, validation, and localized instrument management services required to meet stringent compliance standards.[1, 3, 4, 5] The Distribution segment, contributing roughly 34.5% of annual revenue, focuses on the sale and high-margin rental of new and used handheld instruments.[1, 3, 5] Transcat’s strategic pivot toward high-margin calibration services and rental offerings over the past decade has fundamentally reshaped its economic profile, converting a traditional hardware distributor into a defensive, recurring-revenue compliance business.[1, 2, 5]
The company generates revenue across key geographic markets, primary customer types, and highly regulated end industries.[2, 3] Geographically, Transcat’s revenue is heavily concentrated in the United States, representing more than 90% of consolidated sales, while international operations in Canada and Ireland account for the remainder.[6] This international footprint was strategically expanded on April 9, 2026, with the $13 million cash acquisition of SCM Metrology and Laboratories S.A. (SCM) in Costa Rica, establishing the company’s first physical operating presence in Latin America.[7, 8] SCM operates an ECA-accredited calibration laboratory in the Coyol Free Trade Zone, a dense medical device manufacturing hub, providing an ideal beachhead to capture high-margin multinational life sciences business.[8, 9, 10] Export sales represent less than 10% of total revenue, with Canadian Dollars (CAD) representing 77%, Euros (EUR) 14%, and US Dollars (USD) 9% of those international sales.[6]
| Operating Segment | % of Total FY2026 Revenue | Core Offerings | Key Financial Drivers |
|---|---|---|---|
| Service segment | ~65.5% | ISO/IEC 17025 accredited calibration, pipetting, repair, on-site laboratory services, and validation.[1, 3, 11] | Organic volume, technician utilization, pricing power, and successful acquisition integration.[2, 12, 13] |
| Distribution segment | ~34.5% | Sale and rental of professional-grade handheld measurement and control equipment.[3, 14] | Shift toward higher-margin rentals and industrial capital expenditure cycles.[12, 15, 16] |
Transcat’s core service portfolio addresses parameters such as electrical, dimensional, temperature, and pressure calibration, with specialized niches in mobile calibration, pipette services, and computerized maintenance systems.[1, 3, 11] Its primary customer types consist of blue-chip multinational corporations and local operating facilities requiring highly traceable compliance documentation.[2, 3, 5] The most critical end market is the highly regulated, FDA-governed life sciences space (pharmaceuticals, biotechnology, and medical device manufacturers), which accounts for 60% of total revenue.[1, 5] The remaining vertical exposure is diversified across industrials and materials (16%), aerospace and defense (8%), services and consumer goods (7%), energy and utilities (5%), and other fields (4%).[1, 5]
Multinational clients choose Transcat over fragmented regional competitors due to its expansive geographic scale, the technical depth of its ISO/IEC 17025 accredited parameters, and its proprietary compliance asset management software.[1, 2, 3] Managing calibration across thousands of instruments and multiple operating sites introduces immense regulatory risk, as any single out-of-tolerance instrument can trigger factory shutdowns or product recalls.[2, 17] Transcat provides these clients with a unified, single-source compliance database that standardizes quality control, guarantees documentation traceability, and reduces equipment turnaround times.[2, 3, 18]
The growth trajectory of Transcat is driven by three interconnected levers: organic service volume expansion, the systemic acquisition and integration of regional laboratories, and high-margin product rentals.[12, 13] The organic service business is propelled by secular compliance mandates; as industrial processes become more complex and regulations tighten, the volume of required periodic calibrations naturally expands.[1, 2] The rental business, primarily within the Distribution segment, focuses on temporary instrumentation needs, such as power integrity testing for data centers and specialized field calibrations for remote oil and gas operations.[12, 17] This rental channel is exceptionally profitable, delivering gross margins significantly higher than traditional hardware sales and acting as an immediate catalyst for segment margin expansion.[12, 13, 15]
The metrology market remains highly fragmented, allowing Transcat to act as the consolidator of choice in North America.[1, 5] Its programmatic M&A program is designed to expand geographic coverage, acquire specialized calibration parameters, and unlock cost synergies by moving acquired workloads onto Transcat's localized laboratory networks.[1, 5] In fiscal year 2026, the company successfully completed the acquisition of Essco Calibration Laboratory, representing its largest transaction to date, which added regional density in the New England market.[4, 19, 20] This was followed by the SCM Metrology acquisition in April 2026, marking its international entry into Latin America.[7, 21]
| Targeted Geographic Hubs for Future M&A | Strategic Rationales |
|---|---|
| Costa Rica / Latin America | Leverage SCM's accredited lab to expand into high-growth Central American life science corridors.[9, 21] |
| Northern California | Capture dense concentrations of biotech, pharmaceutical, and high-tech defense clients.[2, 9] |
| Dallas / Atlanta / Mid-Atlantic | Establish localized laboratory density to capture national account field service programs.[2, 9] |
The competitive moat protecting Transcat is reinforced by high customer switching costs.[1, 2] Once a pharmaceutical client integrates Transcat's proprietary asset management software and historical database systems into its standard operating procedures, transitioning to a different vendor creates substantial operational friction.[2, 3] The risk of data loss, compliance gaps, and audit disruptions during a system migration outweighs potential minor cost savings, resulting in client retention rates historically exceeding 90%.[2, 13] Furthermore, Transcat’s national footprint of 33 to 35 commercial labs, embedded client sites, and localized mobile calibration vans establishes a significant barrier to entry, as smaller localized operations lack the capital to replicate such a network.[1, 2, 20]
Credible industry data supports a robust total addressable market (TAM) opportunity.[22] The global calibration services market was valued at $6.76 billion in 2024 and is projected to expand to $7.22 billion in 2025, growing at a compound annual rate of 6.7%.[22] Within this, the United States domestic market is expanding rapidly, expected to reach $1.83 billion by 2025 at a CAGR of 9.8%.[22] Simultaneously, the global test and measurement equipment market is projected to expand from $29.32 billion in 2024 to $59.85 billion by 2035, growing at a CAGR of 7.2%.[22] Transcat's long-term goal of building a $500 million consolidated revenue run-rate within three to five years is well-supported by these market dynamics.[1, 5]
The competitive landscape is bifurcated between global multi-brand service providers and specialized equipment manufacturers.[2, 22] Direct service competitors include global networks like Trescal, Simco Electronics, and Micro Precision Calibration, while hardware-aligned competitors include Fluke Corporation, Tektronix, and Keysight Technologies.[2, 22, 23] Original equipment manufacturers generally prioritize their own brand's hardware, whereas Transcat acts as an independent, multi-brand service provider capable of calibrating entire corporate facilities.[2, 23] The industry remains highly fragmented; in the specialized medical equipment calibration space, leading players such as Fluke, Tektronix, Trescal, and Transcat each hold a modest 3% market share, with the remaining 88% controlled by small, independent operators.[24] Given its public market capital access and strong cash conversion, Transcat is successfully gaining ground, consolidating the market through regional acquisitions and winning national contracts.[5, 25]
Transcat announced its financial and operational results for the fourth quarter and full fiscal year ended March 28, 2026, on Tuesday, May 26, 2026.[15, 26] The company reported solid top-line performance but experienced short-term bottom-line pressure.[15]
Consolidated fourth-quarter revenue reached $89.33 million, representing an increase of 15.8% compared to $77.13 million in the prior-year period.[25, 27] This fell slightly short of some aggressive consensus estimates of $91.59 million (a miss of $2.26 million) [11], while missing alternative estimates of $89.79 million by a minor 0.51% ($0.46 million).[28] Fourth-quarter adjusted diluted earnings per share came in at $0.56.[29, 30] This matched some consensus targets of $0.56 but missed other targets of $0.57 by a penny.[11, 30] GAAP diluted EPS for the quarter fell to $0.21, compared to $0.48 in the prior-year period.[15, 29]
On a full-year basis, fiscal 2026 revenue increased 19.2% to $331.88 million, driven by double-digit growth across both segments.[4, 29] Service segment revenue grew 19.7% to $217.21 million, and Distribution segment revenue rose 18.2% to $114.67 million.[29] Full-year gross profit expanded 21.1% to $108.30 million, with consolidated gross margins expanding 50 basis points to 32.6%.[15, 29] However, full-year GAAP net income decreased 63.0% to $5.38 million (GAAP diluted EPS of $0.57), down from $14.52 million ($1.57 diluted EPS) in fiscal 2025.[15, 29] This GAAP earnings contraction resulted from a 32.8% surge in operating expenses to $95.03 million, driven by non-cash intangible asset amortization from recent transactions, stock-based compensation, and one-time executive transition costs associated with the CEO succession plan.[15, 30, 31] Full-year Adjusted EBITDA grew 22.7% to $48.74 million, expanding margins by 40 basis points to 14.7%.[15, 29]
| Key Financial Metric | Q4 FY2026 | Q4 FY2025 | YoY Change ($) | Full Year FY2026 | Full Year FY2025 | YoY Change (%) |
|---|---|---|---|---|---|---|
| Consolidated Revenue | $89.33M | $77.13M | +$12.20M | $331.88M | $278.42M | +19.2% [4, 29] |
| Service Revenue | $61.57M | $52.01M | +$9.56M | $217.21M | $181.43M | +19.7% [25, 29] |
| Distribution Revenue | $27.76M | $25.12M | +$2.64M | $114.67M | $96.99M | +18.2% [25, 29] |
| Gross Profit | $30.47M | $25.91M | +$4.56M | $108.30M | $89.45M | +21.1% [25, 29] |
| GAAP Net Income | $1.90M | $4.50M | -$2.60M | $5.38M | $14.52M | -63.0% [15, 29] |
| GAAP Diluted EPS | $0.21 | $0.48 | -$0.27 | $0.57 | $1.57 | -63.7% [15, 29] |
| Adjusted EBITDA | $14.80M | $12.80M | +$2.00M | $48.74M | $39.73M | +22.7% [15, 29] |
| Adjusted Diluted EPS | $0.56 | $0.64 | -$0.08 | $1.84 | $2.29 | -19.7% [15, 29] |
By segment, fourth-quarter Service revenue grew 18.4% to $61.57 million, supported by 7.0% organic growth and $5.8 million of acquired revenue from Essco.[25, 31] The Service segment gross margin sequentials improved by 670 basis points in the fourth quarter to 35.5%, indicating that the labor cost headwinds associated with onboarding large new customer wins are beginning to ease.[12, 30, 32] Distribution revenue grew 10.5% to $27.76 million, with gross margins expanding 280 basis points to 31.0%, driven by higher-margin rental offerings for data center and power infrastructure monitoring.[12, 15, 25]
Management provided positive forward guidance for fiscal 2027.[12, 32] President and CEO Jaime Irick guided to high single-digit Service organic revenue growth for fiscal 2027, expecting the first-quarter organic growth rate to exceed the 7.0% achieved in the fourth quarter of fiscal 2026.[30, 32] CFO Thomas Barbato projected that full-year service margins will improve year-over-year in fiscal 2027 compared to fiscal 2026 as onboarding costs normalize.[12, 32] In terms of balance sheet liquidity, Transcat reported operating cash flow of $34.90 million, capital expenditures of $15.30 million, and operating free cash flow of $19.60 million.[15, 33] Total debt stood at $99.90 million under its $150.0 million secured credit facility, with a leverage ratio of 2.03x.[15, 20, 33]
| Balance Sheet & Cash Flow Metric | FY2026 Actuals | Strategic Operational Implications |
|---|---|---|
| Total Debt | $99.90M | Represents increased utilize of credit facility to fund the Essco and SCM acquisitions.[15, 20] |
| Net Debt | $94.90M | Cash balance of $4.9M offsets total debt; leaves $50.1M in credit capacity.[15, 20, 34] |
| Leverage Ratio | 2.03x | Increased from 0.78x in FY25; remains inside comfortable borrowing guidelines.[15, 33] |
| Operating Cash Flow | $34.90M | Healthy cash generation; provides dry powder for capital expenditures and tuck-ins.[15, 33] |
| Capital Expenditures | $15.30M | Directed toward lab technology, corporate systems, and expanding the rental pool.[15, 33] |
| Operating Free Cash Flow | $19.60M | Solid cash flow generation despite heavy working capital and integration investments.[15, 33] |
The market reacted constructively to the earnings announcement.[16, 35] Despite missing some bottom-line estimates, the stock rose 4.08% in aftermarket trading to close at $76.00, signaling investor confidence in sequential service margin recovery and strong rental mix dynamics.[12, 16, 35] Since the late May announcement, the stock has experienced significant upward momentum, trading at $92.88 by mid-June 2026.[36] Analysts maintained a constructive outlook, with consensus targets settling between $101.33 and $105.33.[37, 38, 39]
The most critical financial drivers for valuation are its 13.87% 5-year sales growth CAGR, the shift toward the Service segment, and asset turn efficiency.[5, 40] Because GAAP net income is heavily depressed by non-cash amortization ($4.6M in interest expense and elevated intangible write-downs) [34], traditional P/E ratios (currently at 160.14x trailing [39]) appear artificially elevated. Valuation must be assessed through cash-generation metrics.[15] Transcat's high-compliance business model warrants a premium multiple, as its recurring cash flows are continuously reinvested into high-return rentals and acquisitions.[1, 13]
Transcat's active acquisition strategy introduces integration challenges.[41] Consolidating multiple regional systems, harmonizing quality metrics, and standardizing diverse laboratory teams carries the risk of service disruptions and margin dilution.[2, 41] Onboarding large national customer wins also creates near-term margin pressure, as localized capacity must be added before corresponding revenue flows.[12, 15]
In the lower-barrier Distribution segment, online industrial distributors pressure product pricing.[41] In the Service segment, larger international operators or original equipment manufacturers utilizing proprietary software to restrict third-party servicing could limit Transcat’s market share expansion.[2, 22]
The company has vertical concentration in the life sciences sector, which accounts for 60% of total revenue.[1, 5] While this regulated market is highly defensive, any major policy shift by the FDA regarding validation standards could alter transaction volumes.[3, 42] Additionally, macroeconomic uncertainty has caused small and medium-sized industrial manufacturing clients to soften capital spending, resulting in longer sales cycles.[13, 43]
The company's brand value depends on technical accuracy and data integrity.[2, 3] Transcat must maintain compliance with ISO/IEC 17025 standards and FDA requirements across its network.[1, 3] Any data error, calibration mistake, or regulatory compliance failure could trigger contract cancellations and severe reputational damage.[2]
programmatic acquisitions have pushed total debt to $99.9 million, raising net leverage to 2.03x.[15, 33] This higher debt level in an elevated interest-rate environment has increased interest expense to $4.6 million [34], which could limit free cash flow or necessitate dilutive equity raises.[20, 41]
| Operational Risk Metrics | Early Warning Signs | Long-Term Thesis Impacts |
|---|---|---|
| Integration/Execution | Service organic growth falling below 5% for two consecutive quarters.[15, 25] | Persistent margin compression and high technician turnover.[12, 43] |
| Labor Shortages | Rising average cycle times at primary regional labs.[9, 43] | Increased labor costs and operational bottlenecks.[9, 43] |
| Customer Concentration | Softening volumes from major life science accounts.[5, 43] | Reduced revenue predictability and lower utilization.[2, 42] |
| Balance Sheet Leverage | Leverage ratio rising above 2.50x.[15, 33] | Elevated interest costs and a pause in programmatic M&A.[5, 15] |
| Regulatory Compliance | ISO/IEC accreditation suspensions at local labs.[1, 2] | Significant loss of trust and client contract cancellations.[2] |
While the Service segment is largely insulated from economic cycles, the Distribution segment remains sensitive to industrial capital expenditure trends.[13, 16] Prolonged recessions would eventually weigh on equipment purchasing and rental demand.[13]
An early warning sign of operational deterioration would be Service segment organic growth slowing below the 7.0% threshold, consecutive quarters of sequential gross margin decline, or leverage exceeding 2.50x without an offsetting increase in EBITDA.[15, 25] The long-term investment thesis would be most severely damaged by a systemic regulatory failure, the loss of ISO accreditation at a key regional lab, or a technological shift toward self-calibrating instruments that reduces the outsourced addressable market.[1, 2]
To model Transcat's prospective total returns over the next five years, three detailed operational scenarios are projected. The models utilize a current baseline share price of $92.88 [36], a fiscal 2026 revenue of $331.88 million [4], an Adjusted EBITDA of $48.74 million [29], net debt of $94.90 million [15], and a diluted share count of 9.40 million.[20, 44]
This model assumes Transcat maintains a steady 10.0% revenue CAGR, supported by a return to high single-digit Service organic growth (8.0%) and disciplined regional M&A.[26, 32] This yields Year 5 consolidated revenue of $534.49 million, aligning with management's goal of exceeding $500 million in sales.[1] The calculation is modeled as follows:
$\text{Year 5 Revenue} = 331.88 \times (1 + 0.10)^5 = 534.49 \text{ million USD}$
Service gross margins normalize as customer onboarding headwinds ease, and Adjusted EBITDA margins expand by 130 basis points to 16.0% through operational efficiency, lab density, and growth in the higher-margin rental business.[9, 12] This results in Year 5 Adjusted EBITDA of $85.52 million.[29] Applying a normalized exit EV/EBITDA multiple of 18.0x (a contraction from the current trailing multiple of 23.78x [45]), the Year 5 Enterprise Value is calculated at $1,539.36 million. The company's cash generation is assumed to pay down net debt from $94.90 million to $40.00 million.[15] Accounting for minor dilution from stock incentives, the share count rises to 9.60 million.[46] This yields an implied Year 5 equity value of $1,499.36 million and a projected share price of $156.18 USD, representing a 5-year total return of 68.15% (10.95% annualized).
This model assumes Transcat accelerates its consolidation strategy, achieving a 15.0% revenue CAGR through larger, margin-accretive transactions in high-growth markets like SCM Metrology and higher organic market share gains.[21, 25] This yields Year 5 consolidated revenue of $667.54 million:
$\text{Year 5 Revenue} = 331.88 \times (1 + 0.15)^5 = 667.54 \text{ million USD}$
Adjusted EBITDA margins expand to 18.0% due to strong pricing power in rentals, automated lab processes, and corporate SG&A leverage.[4, 12] Year 5 EBITDA reaches $120.16 million. Benefiting from strong institutional support, the exit EV/EBITDA multiple remains premium at 22.0x, resulting in an Enterprise Value of $2,643.52 million. Net debt is paid down to $20.00 million, while the share count expands to 9.80 million to support equity compensation. The implied Year 5 equity value is $2,623.52 million, yielding a projected share price of $267.71 USD, representing a total return of 188.23% (23.57% annualized).
This model assumes organic growth slows and acquisition integrations face integration challenges.[13] Revenue grows at a 5.0% CAGR, resulting in Year 5 revenue of $423.57 million:
$\text{Year 5 Revenue} = 331.88 \times (1 + 0.05)^5 = 423.57 \text{ million USD}$
Persistent wage inflation and high onboarding costs compress EBITDA margins to 13.0%, resulting in Year 5 EBITDA of $55.06 million.[12, 15] The stock derates due to a slower growth profile, contracting the exit EV/EBITDA multiple to 12.0x. Year 5 Enterprise Value reaches $660.72 million. Net debt increases to $110.00 million due to acquisition costs, while share dilution pushes the count to 10.00 million.[41] The implied Year 5 equity value falls to $550.72 million, yielding a projected share price of $55.07 USD, representing a negative total return of 40.71% (-9.94% annualized).
| Scenario | Year 5 Revenue ($M) | EBITDA Margin % | Exit Multiple (EV/EBITDA) | Current Share Price ($) | Projected Share Price ($) | 5-Year Total Return | Annualized Return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | $667.54 | 18.0% ($120.16M) | 22.0x | $92.88 | $267.71 | 188.23% | 23.57% | 25% |
| Base Case | $534.49 | 16.0% ($85.52M) | 18.0x | $92.88 | $156.18 | 68.15% | 10.95% | 60% |
| Low Case | $423.57 | 13.0% ($55.06M) | 12.0x | $92.88 | $55.07 | -40.71% | -9.94% | 15% |
| Weighted Expected Value | — | — | — | $92.88 | $168.90 | 81.85% | 12.71% | 100% |
Using these probability weights, the expected Year 5 share price is calculated as:
$\text{Expected Share Price} = (267.71 \times 0.25) + (156.18 \times 0.60) + (55.07 \times 0.15) = 168.90 \text{ USD}$
This expected value represents an annualized return of 12.71%, highlighting a constructive asymmetric risk-reward profile driven by fundamental compounding.
ASYMMETRIC COMPOUNDING POTENTIAL
The transition to President and CEO Jaime Irick brings extensive operational leadership experience.[7, 9] Executive compensation is aligned with shareholder interests, utilizing a combination of base pay, performance-based cash bonuses, and restricted stock units (RSUs) tied to Adjusted EBITDA and share value milestones.[47, 48, 49] Direct insider common stock ownership remains low at approximately 2.8%, which limits the score.[39]
Transcat boasts highly resilient revenue streams.[1] The non-discretionary nature of calibration services in heavily regulated spaces, particularly the life sciences vertical (60% of sales), ensures sticky customer relationships and predictable repeating transactions.[1, 5, 42]
The company is the leading multi-brand calibration provider in North America.[1, 3] It is gaining market share through programmatic regional acquisitions, supported by its ability to secure large national contracts.[5, 25]
The outlook remains positive, driven by high single-digit organic Service growth, double-digit rental expansion, and a systematic pipeline of accretive tuck-in M&A.[9, 12]
Balance sheet stability is supported by solid cash conversion and a safe Altman Z-score of 4.04.[15, 34] However, the utilize of debt to fund recent transactions has pushed leverage to 2.03x and increased annual interest costs, which limits the score.[15, 34]
Calibration remains an essential compliance chore with high switching costs.[1, 2] The operational risk of skipping required calibrations or using unaccredited providers makes the business highly durable against cyclical downturns.[2]
Management continues to execute a disciplined capital allocation framework.[5] Capital is deployed toward high-margin rental pool additions and programmatic M&A, supported by solid cash-generation trends.[13, 15]
Sell-side analysts maintain a constructive outlook, with price targets ranging from $101 to $105, reflecting confidence in sequential margin normalization and rental-mix expansion.[37, 38]
Operating profitability is supported by strong gross margins (34.1% in Q4) and high sequential Service margin improvement (670 bps).[15, 25] However, GAAP net margins remain temporarily depressed at 1.6% due to acquisition-related amortization and one-time transition costs, limiting the score.[15, 29]
Transcat has delivered consistent execution over multiple cycles, highlighted by 68 consecutive quarters of year-over-year revenue growth in the Service segment.[12, 25]
The qualitative profile highlights a highly defensive, structurally growing compliance business with sticky client relationships and reliable cash-generation capabilities.
DEFENSIVE QUALITY PROFILE
Transcat’s long-term business model continues to benefit from favorable secular trends.[1] The core investment thesis is supported by the company’s ability to transition its sales mix toward high-margin, recurring compliance Service streams while using its regional network to capture market share.[1, 5] Short-term margin pressure from onboarding large customer wins and financing recent acquisitions has temporarily weighed on GAAP earnings, but underlying cash conversion and Adjusted EBITDA expansion remain solid.[12, 15]
Key operational catalysts over the next twelve months include:
* The normalization of Service gross margins as upfront labor additions are fully absorbed.[12, 32]
* Geographic expansion in Central America leveraging the strategic SCM Metrology footprint in Costa Rica’s medical device hubs.[8, 9, 21]
* Accelerating rental demand for power testing equipment from data centers and utility infrastructure.[12, 17, 33]
While risks regarding acquisition integration and higher interest expense under the revolving credit facility persist, the defensive profile of its core regulated end markets provides substantial downside protection.[15, 34] Based on fundamental analysis, the stock possesses attractive compounding characteristics.[5] The current market valuation appears to undervalue the structural profitability of the service platform once short-term integration charges ease.[15]
STRUCTURAL COMPOUNDING STORY
Transcat’s price action remains in a robust uptrend, with the stock trading at $92.88, significantly above its 200-day moving average of $71.04 and its 50-day moving average of $80.81.[36, 50] The stock has established strong price momentum, gaining over 63% year-to-date and demonstrating a constructive post-earnings breakout in late May.[45, 51] In the immediate short term, the stock is expected to consolidate its recent gains, trading within a range between key support at $74.57 and overhead resistance near $94.76, setting up a solid technical foundation for potential trend extension.[50, 52]
STRONG BULLISH MOMENTUM
View Transcat, Inc. (TRNS) stock page
Loading the interactive version of this report…